Autres langues Takeda Pharmaceutical Company Limited

Actions

4502

JP3463000004

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 24/04/2024			Varia. 5j.	Varia. 1 janv.
4 135 ^JPY	+0,32 %		+0,34 %	+2,00 %

23/04	Takeda investit cinq millions dans le renouvelable à Neuchâtel	AW
22/04	Takeda, Astellas et Sumitomo Mitsui Banking annoncent la signature d'un accord-cadre en vue de la création d'une entreprise commune pour l'incubation de programmes de découverte précoce de médicaments	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	22/04
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	22/04
Takeda Pharmaceutical Wins US FDA Approval for Subcutaneous Administration of Crohn’s Disease Therapy	22/04
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	19/04
Takeda to Hold Fiscal Year 2023 Earnings Call on May 9	19/04
Sector Update: Health Care Stocks Steady Pre-Bell Friday	19/04
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment	19/04
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease	19/04
U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	19/04
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease	18/04
Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds	16/04
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food	08/04
Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited.	01/04
Takeda Announces Approval of ADZYNMA Intravenous Injection 1500 in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura	27/03
Takeda anuncia los candidatos a su Junta Directiva en la próxima asamblea de accionistas	27/03
Takeda gibt Kandidaten für den Vorstand bei der kommenden Aktionärsversammlung bekannt	27/03
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting	27/03
Takeda Pharmaceutical Says Adzynma Gains Approval in Japan to Treat Blood Clotting Disorder	26/03
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	26/03
Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura	26/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Takeda Pharmaceutical Company Limited

Actions

4502

JP3463000004

Autres langues

Filtres